Nanoarmored Probiotic for Inflammatory Bowel Disease Bacteriotherapy via a Dual-Targeting Host-Microbiota Reprogramming
ACS Nano · 30.06.2026 · 20 (25) · 18152-18171
DOI: 10.1021/acsnano.6c02436 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 11.06.2026. Verfasst von Limeng Dou und 19 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Materials Engineering Research Center, State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei Univers…. Hauptthemen laut MEDLINE: Probiotics, Inflammatory Bowel Diseases, Gastrointestinal Microbiome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province, National Key R&D Program of China, Yanzhao Young Scientist Project.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) involves oxidative stress, chronic inflammation, and gut microbiota dysbiosis, complicating therapeutic intervention. Herein, we engineer a robust living therapeutic platform via a biomimetic nanoarmoring strategy. A uniform FDA-approved calcium carbonate (CaCO3) nanocoating is in situ mineralized on the surface of the probiotic Escherichia coli Nissle 1917 (EcN) preassembled with the flavonoid luteolin (Lut), creating the nanocomposite EcN-Lut/CaCO3. This nanoarmoring strategy enhances bacterial viability under simulated gastrointestinal conditions (a 100-fold survival increase) and enables colon-specific delivery. The composite demonstrates potent reactive oxygen species scavenging (∼100%) and immunomodulatory capacity in vitro, downregulating pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-17A) while elevating anti-inflammatory IL-10. In a DSS-induced murine colitis model, EcN-Lut/CaCO3 significantly attenuated disease severity, restoring colon length (a 57.30% recovery compared to healthy control), reducing the disease activity index by 72.73% relative to the DSS group, and improving histopathology. Transcriptomic analysis reveals dual regulation of host signaling pathways with activation of cAMP/cGMP-PKG metabolic cascades and suppression of IL-17/TNF inflammatory pathways. Concurrently, 16S rRNA sequencing shows that the nanoarmored platform effectively reverses dysbiosis, selectively enriching beneficial genera such as Lactobacillus and Muribaculaceae while suppressing proteobacterial pathobionts. This work presents a generalizable nanoarmoring strategy that transforms fragile probiotics into intelligent, multifunctional living therapeutics, offering a powerful approach for the targeted treatment of IBD and other complex inflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Materials Engineering Research Center, State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan 430062, China.
- School of Health Science & Biomedical Engineering, Hebei University of Technology, Tianjin 300401, China.
- State Key Laboratory of Advanced Waterproof Materials, School of Materials Science and Engineering, Peking University, Beijing 100871, China.
- School of Materials Science & Engineering, the Key Laboratory of Advanced Ceramics and Machining Technology by the Ministry of Education of China, Tianjin University, Tianjin 300072, China.
- Department of Orthopaedics & Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong 999077, China.
ORCID-Profile: Xiangmei Liu, Yufeng Zheng, Zhaoyang Li, Shengli Zhu, Hui Jiang, Kelvin Wai Kwok Yeung, Shuilin Wu
Förderung
- Natural Science Foundation of Hubei Province
- National Key R&D Program of China
- Yanzhao Young Scientist Project
- First Batch of Joint Funding (Special Support) from the China Postdoctoral Science Foundation and Hubei Province
- National Natural Science Foundation of China (NSFC)
- Hong Kong Health and Medical Research Fund
Zitieren
APA
Dou, L., Guo, T., Jin, W., Wang, Y., Huang, J., Chen, C., Liu, X., Wang, C., Zheng, Y., Liu, H., Li, Z., Zhu, S., Jiang, H., Cui, Z., Bao, K., Ma, K., Qiao, W., Yeung, K. W. K., Wu, S., & Mao, C. (2026). Nanoarmored Probiotic for Inflammatory Bowel Disease Bacteriotherapy via a Dual-Targeting Host-Microbiota Reprogramming. ACS Nano, 20(25), 18152-18171. https://doi.org/10.1021/acsnano.6c02436
Vancouver
Dou L, Guo T, Jin W, Wang Y, Huang J, Chen C, et al. Nanoarmored Probiotic for Inflammatory Bowel Disease Bacteriotherapy via a Dual-Targeting Host-Microbiota Reprogramming. ACS Nano. 2026;20(25):18152-18171. doi:10.1021/acsnano.6c02436
BibTeX
@article{Dou2026,
author = {Dou, Limeng and Guo, Tong and Jin, Wanyu and Wang, Yi and Huang, Jin and Chen, Cuihong and Liu, Xiangmei and Wang, Chaofeng and Zheng, Yufeng and Liu, Hanpeng and Li, Zhaoyang and Zhu, Shengli and Jiang, Hui and Cui, Zhenduo and Bao, Kai and Ma, Kaiwei and Qiao, Wei and Yeung, Kelvin Wai Kwok and Wu, Shuilin and Mao, Congyang},
title = {Nanoarmored Probiotic for Inflammatory Bowel Disease Bacteriotherapy via a Dual-Targeting Host-Microbiota Reprogramming},
journal = {ACS Nano},
year = {2026},
volume = {20},
number = {25},
pages = {18152--18171},
doi = {10.1021/acsnano.6c02436}
}
EUVIMED